A number of other analysts also recently commented on MRUS. Zacks Investment Research downgraded Merus from a buy rating to a hold rating in a research note on Saturday, August 10th. Roth Capital initiated coverage on Merus in a research note on Friday, June 28th. They issued a buy rating and a $20.00 target price on the stock. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $22.57.
Merus stock opened at $15.77 on Wednesday. The business’s 50-day simple moving average is $15.76 and its two-hundred day simple moving average is $14.14. The company has a market cap of $409.52 million, a PE ratio of -8.57 and a beta of 0.22. Merus has a fifty-two week low of $11.00 and a fifty-two week high of $22.40.
Merus (NASDAQ:MRUS) last posted its quarterly earnings results on Thursday, May 30th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.22. The business had revenue of $8.75 million for the quarter, compared to the consensus estimate of $7.47 million. Merus had a negative return on equity of 41.68% and a negative net margin of 104.10%. Analysts expect that Merus will post -1.73 EPS for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. raised its holdings in Merus by 63.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 8,722 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 3,389 shares during the period. Geode Capital Management LLC raised its holdings in Merus by 18.8% in the 4th quarter. Geode Capital Management LLC now owns 14,987 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 2,373 shares during the period. Athanor Capital LP acquired a new position in Merus in the 2nd quarter worth about $334,000. Granite Investment Partners LLC acquired a new position in Merus in the 1st quarter worth about $468,000. Finally, Morgan Stanley raised its holdings in shares of Merus by 3.1% during the second quarter. Morgan Stanley now owns 92,776 shares of the biotechnology company’s stock valued at $1,359,000 after acquiring an additional 2,788 shares during the last quarter. Hedge funds and other institutional investors own 52.39% of the company’s stock.
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.